Johnson & Johnson

     2011

     2012

Employees: 117,900

Employees: 126,600
Change: 9,700, 8%

Revenues: $65B

Revenues: $67.2B

Only four of the top 10 companies grew their workforce last year, and Johnson & Johnson ($JNJ) was at the top of those four. In fact, the diversified company added more employees than the other three put together. Most of those, 7,000, had nothing to do with its pharma operations. They came on board with Synthes, the company J&J added to its medical device division.

Johnson & Johnson is a highly diversified company and had the revenues to show it, topping the list in sales and the only one of the four to grow revenues last year. Still, the growth in employees contributed to the fact that it falls in the middle of the pack in terms of revenue per employee.

J&J's consumer business continued to flounder, but its new CEO, Alex Gorsky, got to take some credit for growing pharmaceutical revenues. Its $25.4 billion in pharma sales in 2012 represented a 4% boost. U.S. sales were flat, but sales growth outside the home market reached nearly 8%. A number of drugs pushed that along, including its new prostate cancer drug Zytiga. Sales of Zytiga nearly hit the $1 billion blockbuster mark last year and could double this year, after picking up a new indication in both the U.S. and Europe.

J&J managed to grow its business despite a 2% contraction in sales in its consumer health unit. That was on top of a 6% decline the year before. Those sales have been dragged down by the McNeil Consumer Healthcare unit's ongoing struggle to meet the provisions of a consent decree with the FDA, particularly at its Fort Washington, PA, plant, which it closed, gutted and is spending $100 million to retool.

For more:
Johnson & Johnson tops pharma rivals in 10-year test of R&D productivity
J&J pharma growth drives big increase in Q1 sales, profits
J&J, Roche and others back tech platform to bolster translational drug research

Johnson & Johnson
Read more on

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.